First Wave BioPharma’s CEO James Sapirstein to Present at Inaugural Roth Healthcare Opportunities Conference

BOCA RATON, Fla., Sept. 28, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that James Sapirstein, Chairman, President, and CEO of First Wave BioPharma, will give a presentation and take investor meetings at the Inaugural Roth Healthcare Opportunities Conference taking place October 6, 2022, in New York City.

Details of the conference are as follows:

Event:	Inaugural Roth Healthcare Opportunities Conference
Registration:	https://www.meetmax.com/sched/event_88609/conference_home.html
Date:	Thursday, October 6, 2022
Time:	1.15 P.M. ET
Location:	The Yale Club, New York City

About First Wave BioPharma, Inc.First Wave BioPharma is a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The Company is currently advancing a therapeutic development pipeline with multiple clinical stage programs built around its two proprietary technologies – the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients, and niclosamide, an oral small molecule with anti-inflammatory properties. First Wave is advancing two Phase 2 clinical programs built around adrulipase for the treatment of exocrine pancreatic insufficiency (FW-EPI) in patients with cystic fibrosis (CF) and chronic pancreatitis (CP). In developing adrulipase, First Wave is seeking to provide CF and CP patients with a safe and effective therapy to control EPI that is non-animal derived and offers the potential to dramatically reduce their daily pill burden. The company is also advancing multiple programs involving niclosamide, including FW-UP for ulcerative proctitis and ulcerative proctosigmoiditis, FW-UC for ulcerative colitis, and FW-CD for Crohn’s disease. First Wave BioPharma is headquartered in Boca Raton, Florida. For more information visit www.firstwavebio.com.

For more information:First Wave BioPharma, Inc.777 Yamato Road, Suite 502Boca Raton, FL 33431Phone: (561) 589-7020[email protected]

Media contact:Tiberend Strategic Advisors, Inc.David Schemelia(609) 468-9325 [email protected]

Source: First Wave BioPharma, Inc.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• HAVILA KYSTRUTEN AS: Refinancing completed
• West Red Lake Gold Intersects 68.36 g/t Au over 1.1m and 13.83 g/t Au over 3.95m at South Austin Zone – Madsen Mine
• ICG : Notification of Major Holdings